EBIT: Income before interest and taxes.
Regeneron Pharmaceuticals, Inc. (REGN) had EBIT of $3.99B for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
$14.20B |
|
$4.41B |
|
$1.97B |
|
$12.23B |
|
$10.21B |
|
$3.99B |
|
$789.20M |
|
$4.78B |
|
$4.78B |
|
$4.41B |
|
$4.41B |
|
$4.41B |
|
$4.41B |
|
|
EBIT |
$3.99B |
$4.47B |
|
107.90M |
|
115.10M |
|
$40.90 |
|
$38.34 |
|
| Balance Sheet Financials | |
$18.66B |
|
$4.60B |
|
$19.10B |
|
$37.76B |
|
$3.94B |
|
$2.70B |
|
$4.46B |
|
$8.41B |
|
$29.35B |
|
$28.20B |
|
$29.35B |
|
109.60M |
|
| Cash Flow Statement Financials | |
$4.42B |
|
$-2.47B |
|
$-2.20B |
|
$2.74B |
|
$2.49B |
|
$-248.80M |
|
$982.80M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.73 |
|
-- |
|
-- |
|
0.08 |
|
0.09 |
|
86.13% |
|
28.10% |
|
28.10% |
|
31.50% |
|
33.66% |
|
31.07% |
|
$3.68B |
|
-- |
|
-- |
|
-- |
|
0.38 |
|
0.64 |
|
2.29 |
|
159.65 |
|
15.03% |
|
15.64% |
|
11.69% |
|
13.76% |
|
$267.82 |
|
$32.01 |
|
$38.41 |
|